Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide (opens in new tab)

ObjectiveSemaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction. Vitamin D has been implicated in metabolic regulation, yet its influence on semaglutide-induced outcomes remains unclear.Research design and methodsWe conducted a retrospective cohort study of 5,384 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and Decembe...